Articles related to DEPRESSION

In this study involving 452 patients with diagnoses of MDD, GAD, and PTSD, IM ketamine reduced depression by 38% and anxiety by 50%, with persistence over 7 months of maintenance therapy.

To test whether low doses of the NMDA-receptor partial-agonist D-cycloserine would enhance intermittent TBS (iTBS) treatment outcomes in MDD, this single-site 4-week, double-blind, placebo-controlled, randomized clinical trial compared TBS with D-cycloserine vs. TBS with placebo. The TBS plus D-cycloserine group had greater improvements in MADRS scores compared with the iTBS plus placebo group, with a mean difference of −6.15.

Data from the open label Evaluation of NMDA Modulation for Depressive Episodes (EVOLVE) study presented at Psych Congress 2022 showed a significant decrease in HAM-A scores at 1 week, with further decreases in scores observed through 12 months.

In treatment-resistant depression, two studies found that COMP360 psilocybin therapy reduced depression and one study reported that using precision medicine for ketamine dosing might decrease the high efficacy-low effectiveness gap.

Incidences of dizziness, dissociation, increased blood pressure, nausea, vertigo, and sedation were highest in week 1 of treatment and the majority are mild or moderate in severity.

In this interview with Dr. Wendy Marsh, director of the Bipolar Disorders and Depression Specialty Clinics at the University of Massachusetts Chan Medical School, she discusses how treatment can better address quality-of-life issues for individuals with bipolar depression.